AUS
NZ
UK
CA
USA
IND
Enlitic Inc. (ASX:ENL), a medical AI company listed on the ASX through CHESS Depositary Interests, has revealed plans for a two-part capital raise consisting of a placement of up to 3,750,000,000 CDIs and a Securities Purchase Plan (SPP) offering up to 250,000,000 CDIs to eligible shareholders. Announced on 3 July 2026, this combined capital raising aims to secure funds for general corporate and working capital needs while allowing flexibility to advance the company’s strategic commercial goals. Key milestones such as shareholder approval and ASX waiver applications must be met before the SPP can proceed unconditionally. The placement is anticipated to settle on 7 August 2026, with the SPP closing on 28 August 2026 and issuing on 4 September 2026.
Key Points
- Company: Enlitic Inc. (ASX:ENL)
- Proposed placement of up to 3,750,000,000 CDIs and an SPP offering up to 250,000,000 CDIs
- SPP price set at the lower of A$0.004 or a 2.5% discount to the five-day VWAP at SPP close; maximum subscription capped at A$1,000,000
- Shareholder approval for the SPP required by 31 July 2026; ASX waiver applications to be submitted
- Placement expected to issue on 7 August 2026; SPP offer documents available from 10 August 2026, closing 28 August 2026
- Investors should monitor shareholder vote outcomes, ASX waiver decisions, and potential scale-back announcements
Overview of Enlitic’s Placement and Securities Purchase Plan Capital Raise
Enlitic Inc. has lodged an Appendix 3B with the ASX confirming a proposed securities issue in two parts. The first tranche is a placement of up to 3,750,000,000 CHESS Depositary Interests (CDIs) on a 1:1 basis, excluding US participants, with a proposed issue date of 7 August 2026. The second tranche is a Securities Purchase Plan open to eligible shareholders, offering up to 250,000,000 CDIs, scheduled for issue on 4 September 2026.
This dual-tranche approach balances rapid capital raising through institutional or sophisticated investors via the placement while allowing retail shareholder participation through the SPP. The record date for SPP eligibility was 2 July 2026, meaning shareholders on the register at that date may participate subject to conditions.
Details of the SPP Pricing Mechanism and Participation Terms
The SPP offer price will be the lower of A$0.004 per CDI—the same as the placement price—or a 2.5% discount to the volume-weighted average price (VWAP) of ENL CDIs over the five trading days before the SPP closes, rounded to the nearest A$0.001. This ensures SPP participants pay no more than placement investors and may benefit from any price decline before 28 August 2026.
Eligible shareholders can apply for parcels ranging from A$1,000 up to A$30,000, with minimum and maximum application amounts set accordingly. The total SPP subscription is capped at A$1,000,000. Should applications exceed this cap, Enlitic reserves the right to scale back applications at its discretion.
Conditions for SPP Progression: Shareholder Approval and ASX Waivers
The SPP is conditional upon shareholder approval, which must be obtained by 31 July 2026. As of the announcement date, this approval had not been secured. Additionally, Enlitic plans to apply for certain ASX waivers related to the shareholder approval requirements, though details of these applications were not disclosed in the filing.
Investors should closely follow updates regarding the shareholder meeting and ASX waiver outcomes, as these are prerequisites for the SPP to proceed when the offer opens on 10 August 2026.
Impact on Capital Structure: Potential Issuance of Up to 4 Billion New CDIs
The combined maximum issuance under the placement and SPP totals 4,000,000,000 CDIs—3,750,000,000 from the placement and 250,000,000 from the SPP. This significant increase could lead to notable dilution for existing shareholders who do not participate.
While the filing did not state a total gross proceeds figure, applying the placement price of A$0.004 per CDI to the maximum placement amount suggests potential gross proceeds of approximately A$15 million. The SPP is separately capped at A$1 million.
Use of Capital: Supporting Working Capital and Strategic Objectives
Enlitic intends to use the funds raised for general corporate and working capital purposes and to maintain flexibility in pursuing strategic commercial initiatives. The company’s disclosures dated 3 July 2026 provide additional context on the strategic rationale behind the capital raise.
Operating in the medical AI field focused on healthcare data standardisation and AI-driven diagnostic imaging, Enlitic’s capital raise aligns with common practices among growth-stage technology firms to extend operational runway and support product and business development. Specific allocation details were not provided.
Placement Settlement and Issuance Timeline
The placement tranche is scheduled to issue on 7 August 2026, approximately five weeks after the announcement. This timeline is typical for institutional placements, which do not require extended offer periods.
The placement CDIs are restricted from US participation and represent a 1:1 interest in Enlitic Inc., a US-registered entity (ARBN 672254027). The filing did not disclose any lead manager or broker involvement, and the placement is not underwritten.
SPP Offer Schedule and Application Process
SPP offer documents will be released on 10 August 2026, coinciding with the opening of the offer. Eligible shareholders will have until 28 August 2026 to submit applications. The new CDIs from the SPP will be issued on 4 September 2026, the same day Enlitic will announce the offer results.
New CDIs issued under both the placement and SPP will rank equally with existing CDIs from their respective issue dates.
Scale-Back Provisions Under the A$1 Million SPP Cap
Although individual shareholders may apply for up to A$30,000, the overall SPP is capped at A$1,000,000. With a minimum application of A$1,000, the cap could be reached with as few as 1,000 minimum applications. If demand exceeds the cap, Enlitic may scale back applications at its sole discretion without a disclosed formula.
Applicants should be aware that larger applications may not be fully filled if oversubscription occurs. Details on any scale-back will be provided when SPP results are announced on or before 4 September 2026.
Cost Structure: No Underwriting or Broker Fees
The SPP is not underwritten, and brokers submitting acceptances on behalf of security holders will not receive handling fees or commissions. The company indicated no other significant fees or costs apply to the offer.
Without underwriting, Enlitic assumes the risk of the SPP not reaching full subscription. However, the A$1 million cap limits potential shortfall, and the placement tranche is expected to provide the majority of capital raised. The company’s dividend or distribution policy is not expected to change if the capital raise succeeds.
Investor Considerations: Monitoring Key Milestones and Outcomes
The crucial upcoming milestone is shareholder approval by 31 July 2026, without which the SPP cannot proceed unconditionally. Investors should watch for shareholder meeting notices detailing the resolution and supporting information. ASX waiver application outcomes are also important, as any denial could affect the SPP’s structure or timing.
Following these procedural steps, investors will focus on the placement results expected around 7 August 2026 and subsequent updates on how the capital raised will support Enlitic’s strategic plans. The immediate share price impact was unclear at the time of this report. Eligible shareholders should review the SPP offer documents upon release on 10 August 2026 and submit applications before the 28 August 2026 deadline.
